Gilead has already had success with the single-pill combination therapy in the ARTISTRY-1 trial.
If varegacestat gets FDA approval, it could challenge Ogsiveo’s desmoid tumour market dominance.
Aviceda said that the candidate will be investigated in two Phase III trials which are due to begin in 2026.
Increasing clinical trial activity across the APAC region is impacting global commercial supply routes.
The decision comes after the committee recommended halting the studies for futility after reviewing interim data.
Initial data on tolerability, safety, and brain imaging from the participants are expected in 2026.
